Screening and biological evaluation of novel anticancer agents and lipid profiling of autophagy-related proteins

dc.contributor
Universitat de Barcelona. Facultat de Farmàcia i Ciències de l'Alimentació
dc.contributor.author
Quintana Agustí, Mireia
dc.date.accessioned
2019-10-17T10:10:34Z
dc.date.available
2020-09-29T02:00:15Z
dc.date.issued
2019-09-30
dc.identifier.uri
http://hdl.handle.net/10803/667690
dc.description
Programa de Doctorat de Biotecnologia / Tesi realitzada a l'Institut de Química Avançada de Catalunya (IQAC)
dc.description.abstract
This thesis addresses three different subjects closely related. First, a phenotypic screening measuring cytotoxicity in the gastric cancer cell line HGC-27 is reported. Next, a targeted-based assay measuring the activity of autophagy-related protein Atg4B is developed and employed to identify small-molecule inhibiting this protein. Finally, a basic research study is carried out to gain knowledge of the molecular mechanisms that control autophagy. The first chapter of this thesis covers the study of a variety of squaramates and squaramides and their cytotoxic activity in different cancer cell lines. The squaramide 34 showed a potent and selective cytotoxicity against the human gastric cancer cell line HGC-27. Studies directed to elucidate the mechanism of induced cell death were performed. Cell cycle distribution analysis and cell death studies showed that compound 34 induces cell cycle arrest at the G0/G1 phase and caspase-dependent apoptosis implicating the intrinsic pathway and mitochondrial membrane depolarization. In conclusion, squaramide 34 can be considered a potential anticancer agent for gastric carcinoma. Drug resistance is a major issue in oncology and a limiting factor for anticancer drug efficacy. Autophagy induction is employed by cancer cells as a survival mechanism, therefore, the employment of autophagy inhibitors as adjuvant treatment could increase the anticancer drug efficacy. The second chapter of this thesis is focused on the development of a novel AlphaScreen-based HTS assay and a Mass spectrometry- based counter screen to identify Atg4B inhibitors. A high-throughput virtual screening performed with the National Cancer Institute Open Database library and subsequent evaluation of 250 selected compounds allowed the identification of three potential inhibitors (NSC83713, NSC126353 and NSC611216). Derivatives of them were synthesised and their characterization by both techniques allowed the discovering of most active compounds 54, 55, 56 and 57. Compound 57 was chosen for additional characterization based on its high potency and good cytotoxicity profile on cell lines. Inhibition of the autophagic flux was maintained and the synergistic effect of 57 combined with oxaliplatin resulted in an enhanced cell death in the human cell line HT-29. In conclusion, the aminobenzo[cd]indol-2-[1H]-one scaffold represents a novel chemotype for the development of small molecule inhibitors of Atg4B. The conjugation of a phosphatidylethanolamine (PE) unit at the C-terminus of LC3 is essential for the autophagy regulation. Despite the high variability described in cellular lipids, a potential role of heterogenous lipidation on protein activity has not been considered. Hence, the third chapter of this thesis is focussed on the development of a lipidomic approach for the study of the PE species conjugated to LC3/GABARAP. The method relies on the enzymatic release of the protein-bound lipids mediated by Atg4B incubation. The strategy is applied to the whole proteome and proteins isolated by immunoaffinity techniques. Preliminary results could not succeed in the analysis of the lipid bound proteins. Moreover, lipid contamination of the enzyme difficulted the establishment of the lipidomic approach.
dc.format.extent
420 p.
dc.format.mimetype
application/pdf
dc.language.iso
eng
dc.publisher
Universitat de Barcelona
dc.rights.license
ADVERTIMENT. L'accés als continguts d'aquesta tesi doctoral i la seva utilització ha de respectar els drets de la persona autora. Pot ser utilitzada per a consulta o estudi personal, així com en activitats o materials d'investigació i docència en els termes establerts a l'art. 32 del Text Refós de la Llei de Propietat Intel·lectual (RDL 1/1996). Per altres utilitzacions es requereix l'autorització prèvia i expressa de la persona autora. En qualsevol cas, en la utilització dels seus continguts caldrà indicar de forma clara el nom i cognoms de la persona autora i el títol de la tesi doctoral. No s'autoritza la seva reproducció o altres formes d'explotació efectuades amb finalitats de lucre ni la seva comunicació pública des d'un lloc aliè al servei TDX. Tampoc s'autoritza la presentació del seu contingut en una finestra o marc aliè a TDX (framing). Aquesta reserva de drets afecta tant als continguts de la tesi com als seus resums i índexs.
dc.source
TDX (Tesis Doctorals en Xarxa)
dc.subject
Biologia molecular
dc.subject
Biología molecular
dc.subject
Molecular biology
dc.subject
Lípids
dc.subject
Lípidos
dc.subject
Lipids
dc.subject
Proteïnes
dc.subject
Proteínas
dc.subject
Proteins
dc.subject
Cultiu cel·lular
dc.subject
Cultivo celular
dc.subject
Cell culture
dc.subject
Autofàgia
dc.subject
Autofagia
dc.subject
Autophagy
dc.subject.other
Ciències de la Salut
dc.title
Screening and biological evaluation of novel anticancer agents and lipid profiling of autophagy-related proteins
dc.type
info:eu-repo/semantics/doctoralThesis
dc.type
info:eu-repo/semantics/publishedVersion
dc.subject.udc
577
dc.contributor.director
Triola i Guillem, Gemma
dc.contributor.tutor
Badía Palacín, Josefa
dc.embargo.terms
12 mesos
dc.rights.accessLevel
info:eu-repo/semantics/openAccess


Documents

MQA_PhD_THESIS.pdf

19.65Mb PDF

Aquest element apareix en la col·lecció o col·leccions següent(s)